Hospira Launches First Biosimilar Monoclonal Antibody (mAb) InflectraTM (Infliximab) in Major European Markets
LAKE FOREST, Ill., February 16, 2015 — Hospira, Inc. (NYSE: HSP), a world leader in the development of biosimilar therapies, today announced the launch…